Tirzepatide Dosing: The Complete Escalation Protocol for Weight Loss

# Tirzepatide Dosing: The Complete Escalation Protocol for Weight Loss

Tirzepatide (brand names Zepbound for weight loss, Mounjaro for diabetes) is a dual GIP/GLP-1 receptor agonist — the only approved medication to target both incretin pathways simultaneously. This dual mechanism contributes to its superior weight loss outcomes compared to GLP-1-only medications.

But that potency comes with a real need for careful dose escalation. Here's everything you need to know about tirzepatide dosing.

The Standard Escalation Schedule

Tirzepatide is approved in weekly injection doses: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, and 15mg.

The FDA-approved titration schedule:

| Period | Weekly Dose | |---|---| | Weeks 1-4 | 2.5mg | | Weeks 5-8 | 5mg | | Weeks 9-12 | 7.5mg | | Weeks 13-16 | 10mg | | Weeks 17-20 | 12.5mg | | Week 21+ | 15mg (maximum) |

Each step represents 4 weeks at the same dose before escalating. This is the schedule used in the SURMOUNT trials, which achieved 20-22% mean body weight reduction at 72 weeks.

Why the Gradual Escalation?

Tirzepatide's most common side effects — nausea, vomiting, diarrhea, constipation — are dose-dependent and primarily occur during and after dose increases. The gradual escalation allows the GI tract time to adapt.

Rushing escalation doesn't produce meaningfully better weight loss outcomes and significantly worsens tolerability. The 4-week intervals are clinically validated.

Key principle: Never escalate if you're still experiencing significant GI side effects at your current dose. Side effects typically peak in the first 1-2 weeks at a new dose and improve with continued use.

2.5mg: The Starting Dose (Weeks 1-4)

The 2.5mg starting dose is purely a titration dose — it produces minimal weight loss on its own. Its purpose is to allow your body to begin adapting to the medication with minimal side effects.

What to expect: - Mild appetite reduction (noticeable but not dramatic) - Possible mild nausea, particularly after injection day - Some patients feel nothing significant — this is normal

Common mistake: Expecting dramatic effects at 2.5mg and concluding the medication "isn't working." Give the full titration schedule time.

5mg: First Therapeutic Dose (Weeks 5-8)

5mg is where most patients begin noticing meaningful appetite suppression. Weight loss becomes more apparent.

What to expect: - More pronounced appetite reduction - Nausea and/or loose stools possible in first 1-2 weeks after escalation - Most patients tolerate 5mg reasonably well after the initial adjustment

If experiencing significant nausea: extend the 5mg period by an additional 2-4 weeks before escalating. Tolerability at each dose takes precedence over schedule.

7.5mg: The Sweet Spot for Many Patients (Weeks 9-12)

Many patients find their optimal balance of efficacy and tolerability in the 5-10mg range. 7.5mg is a middle step.

Clinical trial data: About 15% of patients in SURMOUNT-1 achieved their weight loss goals and maintained at 7.5-10mg without needing to escalate further.

10mg-15mg: Maximum Efficacy Range

The 10mg-15mg doses produce the most weight loss. In SURMOUNT-1: - 5mg: ~15% weight loss at 72 weeks - 10mg: ~19.5% weight loss - 15mg: ~20.9% weight loss

The incremental gains from 10mg to 15mg are modest (about 1-2% additional weight loss), but they're real. For patients who can tolerate 15mg, it remains the most effective dose.

Maintenance Dosing

"Maintenance dose" refers to the dose at which weight loss has plateaued and the goal becomes sustaining that loss. This isn't a specific prescribed dose — it's whatever dose keeps your weight stable.

Some patients genuinely maintain at 5mg. Others need 15mg for maintenance. The goal is finding the minimum effective dose for your response and goals.

If you've reached goal weight at a lower dose, your physician may try stepping down to see what's needed for maintenance — but this should be done cautiously, as rebound weight gain on GLP-1 discontinuation is well-documented.

Managing Side Effects During Escalation

Nausea: - Inject at night before bed — you'll sleep through the worst of it - Eat small, bland meals after injection day - Avoid high-fat and spicy meals in the first 24-48 hours post-injection - Stay hydrated - Over-the-counter antiemetics (ginger, Dramamine) can help mild nausea

Vomiting: If vomiting frequently, do not escalate. Stay at current dose until it resolves. Contact your physician if vomiting persists more than 2-3 days.

Constipation: Common on GLP-1/GIP agonists. Increase fiber and fluid intake. Magnesium citrate can help. Your physician can advise on safe use of stool softeners if needed.

Diarrhea: Usually self-limited. Stay hydrated, follow BRAT diet (bananas, rice, applesauce, toast) for a day or two after escalation.

Slowing or Pausing Escalation

There is no penalty for taking longer to reach your target dose. Many patients benefit from a modified schedule: - 6-8 weeks at each dose instead of 4 - Pausing at a well-tolerated dose rather than pushing higher - Skipping a dose increment if side effects are significant

Discuss any protocol modifications with your physician. The goal is sustainable treatment, not speed.

Injection Technique

Tirzepatide is injected subcutaneously (under the skin) once weekly. Recommended sites: - Abdomen (avoid the 2-inch zone around navel) - Outer thigh - Upper arm (less preferred — harder to self-administer)

Rotate injection sites each week. Inject at a 45° angle for leaner patients, 90° for more subcutaneous tissue. Allow the medication to reach room temperature before injecting.

At Marrow, your prescribing physician tailors the escalation protocol to your tolerance and response. [Start your consultation →](/start)